1. Home
  2. AVLN vs CHY Comparison

AVLN vs CHY Comparison

Compare AVLN & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$38.37

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo Calamos Convertible and High Income Fund

CHY

Calamos Convertible and High Income Fund

HOLD

Current Price

$13.03

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVLN
CHY
Founded
N/A
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2026
2003

Fundamental Metrics

Financial Performance
Metric
AVLN
CHY
Price
$38.37
$13.03
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
163.8K
172.7K
Earning Date
N/A
01-01-0001
Dividend Yield
N/A
10.11%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.90
$10.41
52 Week High
$40.17
$13.91

Technical Indicators

Market Signals
Indicator
AVLN
CHY
Relative Strength Index (RSI) 67.65 47.52
Support Level $26.38 $12.06
Resistance Level $40.08 $13.11
Average True Range (ATR) 2.60 0.17
MACD 0.54 0.00
Stochastic Oscillator 94.55 33.57

Price Performance

Historical Comparison
AVLN
CHY

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

About CHY Calamos Convertible and High Income Fund

Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.

Share on Social Networks: